DOCSLIB.ORG

Final List- Generic Drugs SPELL CHECK.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final List- Generic Drugs SPELL CHECK.Xlsx SL.NO GENERIC NAME Unit 1 ABDOMINAL CORSET SEGO LARGE LARGE 2 ABDOMINAL CORSET SEGO MEDIUM MEDIUM 3 ABDOMINAL CORSET SMALL SMALL 4 ABGEL ABGEL 5 ACEBROFYLLINE+ACETYLCYSTEINE 100mg,+ 600mg TABLET 6 ACEBROPHYLLINE 100MG CAPSULE 7 ACEBROPHYLLINE 200SR CAPSULE 8 ACECLOFENAC 100 MG+PARACETAMOL 325MG TABLET 9 ACECLOFENAC 100MG TABLET 10 ACECLOFENAC 100MG,PARACETAMOL 325MG,TRAMADOL 375MG TABLET 11 ACECLOFENAC 100MG,PARACETAMOL 500MG,TIZANIDINE 2MG CAPSULE 12 ACECLOFENAC 100MG+PARACETAMOL 650MG TABLET 13 A‐ CELLULER D TAP INJECTION 14 ACELOFENAC+RABIPRAZOLE TABLET 15 ACECLOFENAC+SERRATIOPEPTIDASE+PARACETAMOL (100+15+500)MG TABLET 16 ACECLOPENAC 200MG CAPSULE 17 ACENOCOUMAROL 2mg TABLET 18 ACEPTO SYRINGE PIECES 19 ACETAMINOPHEN 250 SYRUP 20 ACETAMINOPHEN 250MG 60ML SYRUP 21 ACETAMINOPHEN & PARACETAMOL TABLET 22 ACETAZOLAMIDE 250 TABLET 23 ACETYLACETYLIN SOLUTION 5ML INJECTION 24 ACETYLCYSTEINE 600MG TABLET 25 ACETYLCYSTEINE 600MG Respules ACETYL SALICYLIC ACID 350MG, CALCIUM CARBONATE 35MG, CITRIC ACID 105MG TABLET 26 27 ACICLOVIR 200MG TABLET 28 ACICLOVIR 250MG INJECTION 29 ACICLOVIR 30ML SYRUP 30 ACICLOVIR 400MG TABLET 31 ACICLOVIR 500MG INJECTION 32 ACICLOVIR 800MG TABLET 33 ACICLOVIR EYE 5% 5GM OINTMENT 34 ACICLOVIR 5GM EYE O OINTMENT 35 ADAPALENE APGEL 36 ADAPALENE TOPICAL 01%W/W,CLINDAMYCIN TOPICAL 1%W/W GEL 37 ADENOSINE 2ML INJECTION 38 ADHESIVE TAPE 4 INCH GPLAST PIECES 39 ADRENALINE 1ML INJECTION 40 ADULT DIAPER 10 LARGE LARGE 41 ADULT DIAPER 10 MEDIUM MEDIUM 42 ADULT DIAPER 5 LARGE LARGE 43 ADULT DIAPER 5 MEDIUM MEDIUM 44 AIR MITTRESS PIECES 45 AIRWAY 1 PIECES 46 AIRWAY NO‐02 PIECES 47 AIRWAY NO‐03 PIECES 48 AIRWAY NO‐45 PAED NO‐4 PIECES 49 ALANYL‐GLUTAMINE‐DIPEPTIDE DIPEPTIVEN 50 ALBENDAZOLE+IVERMECTOL TABLET 51 ALBENDAZOLE 10ML SYRUP 52 ALBENDAZOLE 400MG TABLET 53 ALBUMIN 100ML TABLET 54 ALENDRONIC ACID 70MG TABLET 55 Aloe Vera Gel,Light Liquid Paraffin,Calamine 100ml LOTION 56 ALOEVERA GEL+GLYCERINE 100ML LOTION 57 ALLOPURINOL 100MG TABLET 58 ALLOPURINOL 300MG TABLET 59 ALPHA‐AMYLASE+PAPAIN+ANISE OIL 2MG DROP 60 ALPHA‐AMYLASE100MG,PAPAIN50MG/5ML100ML SYRUP 61 ALPHA AMYLASE 100ML SYRUP 62 ALPHA LIPOIC ACID CAPSULE 63 ALPRAZOLAM 0.5MG TABLET ALUMINIUM HYDROXIDE 300MG,MAGNESIUM ALUMINIUM SILICATE 50MG, MAGNESIUM TABLET 64 HYDROXIDE 25MG,SIMETHICONE 25MG 65 ALUMINUM HYDROXIDE AND MAGNESIUM HYDROXIDE 170ML Syrup 66 AMBROXOL 15MG Respules 67 AMBROXOL 30MG, GUAIPHENESIN 50MG/5ML,SALBUTAMOL 1ML SYRUP 68 AMBROXOL 75MG TABLET 69 AMIKACIN 100MG INJECTION 70 AMIKACIN 250MG INJECTION 71 AMIKACIN 500MG INJECTION 72 AMINO ACID POWDER 73 AMINO ACIDS,ELECTROLYTES,DEXTROSE AND LIPID INJECTABLE EMULSION FLUIDS 74 AMINOPHYLLIN 10ML INJECTION 75 AMINOVEN 10% 500ML NUTRITION 76 AMIODARONE HCL 100MG TABLET 77 AMIODARONE HCL (150MG 3ML) INJECTION 78 AMIODARONE HCL 200mg TABLET 79 AMI SULPHIDE 200MG TABLET 80 AMITRIPTYLINE 10MG TABLET 81 AMITRIPTYLINE 25MG TABLET 82 AMITRIPTYLINE 50MG TABLET 83 AMLODIPINE & ATENOLOL TABLET 84 AMLODIPINE+HYDROCLORTHIAZIDE TABLET 85 AMLODIPINE 10MG TABLET 86 AMLODIPINE 5MG TABLET 87 AMMONIUM CHLORIDE 60MG,CPM 25MG,DEXTROMETHORPHAN 5MG,GUAIPHENESIN SYRUP 88 AMOROLFINE HCL CREAM 89 AMOXICILLIN 125MG TABLET 90 AMOXICILLIN 200MG,CLAVULANIC ACID 285MG HS30ML SYRUP 91 AMOXICILLIN 250MG TABLET 92 AMOXICILLIN 250MG CAPSULE 93 AMOXICILLIN 30ML SUSPENSION 94 AMOXICILLIN 400MG,CLAVULANIC ACID 57MG DS 30ML SYRUP 95 AMOXICILLIN 500MG TABLET 96 AMOXICILLIN 750MG,PANTOPRAZOLE 40MG,CLARITHROMYCIN 500MG TABLET 97 AMOXICILLIN AND CLAVULANATE POTASSIUM 1.2GM INJECTION 98 AMOXICILLIN AND CLAVULANATE POTASSIUM 1GM TABLET 99 AMOXICILLIN AND CLAVULANATE POTASSIUM 300MG INJECTION 100 AMOXICILLIN AND CLAVULANATE POTASSIUM 30ML SYRUP 101 AMOXICILLIN AND CLAVULANATE POTASSIUM 375MG TABLET 102 AMOXICILLIN AND CLAVULANATE POTASSIUM 50ML SYRUP 103 AMOXICILLIN AND CLAVULANATE POTASSIUM 600MG INJECTION 104 AMOXICILLIN AND CLAVULANATE POTASSIUM 625MG TABLET 105 AMOXICILLIN AND CLAVULANATE POTASSIUM DDS SYRUP 106 AMPICILLIN+CLOXACILLIN 250MG TABLET 107 AMPICILLIN+CLOXACILLIN 500MG CAPSULE 108 AMPICILLIN+CLOXACILLIN 500MG INJECTION 109 AMPICILLIN+CLOXACILLIN 60ML SYRUP 110 AMPICILLIN 500MG CAPSULE 111 AMPICILLIN 500MG INJECTION 112 ANKLE BINDER LARGE 113 ANKLE BINDER EXTRA LARGE EXTRALARGE 114 ANKLE BINDER MEDIUM MEDIUM 115 ANKLE SUPPORT LARGE 116 ANKLE SUPPORT MEDIUM 117 ANKLE SUPPORT SMALL 118 ANTIASTHMA AND COPD PRODUCTS 250MG ROTAHELAR 119 ANTI D IMMUNOGLOBULIN INJECTION 120 ANTI EMBOLISM STOCKING MEDIUM 121 ANTI EMBOLISM STOCKING LARGE SHORT 122 ANTI EMBOLISM STOCKING MEDIUM SHORT 123 ANTI EMBOLISM STOCKING SMALL SHORT 124 ANTI EMBOLISM STOCKING LARGE REGULAR 125 ANTIOXIDANT & MULTIVITAMINS CAPSULE 126 ANTISEPTIC 100ML SOLUTION 127 ARIPIPRAZOLE 10MG TABLET 128 ARM SLING CHILD 129 ARM SLING E.LARGE 130 ARM SLING MEDIUM 131 ARM SLING SMALL 132 ARM SLING LARGE 133 ASPIRIN 150MG TABLET 134 ASPIRIN 75MG TABLET 135 ASPIRIN 75MG,CLOPIDOGREL 75MG CAPSULE 136 ASPRIN+ATORVASTATIN TABLET 137 ASPRIN+ATORVASTATIN 150MG TABLET 138 ASPRIN+ATORVASTATIN 75MG TABLET 139 ASPRIN 375MG TABLET 140 ATENOLOL 25MG TABLET 141 ATENOLOL 50MG TABLET 142 ATORVASTATIN 10MG TABLET 143 ATORVASTATIN 20MG TABLET 144 ATORVASTATIN 40MG TABLET 145 ATORVASTATIN 80MG TABLET 146 ATORVASTATIN AND FENOFIBRATE 145 TABLET 147 ATORVASTATIN AND FENOFIBRATE TG TABLET 148 ATRACURIUM 2ML INJECTION 149 ATROPIN 10ML EYE DROP DROP 150 ATROPINE SULFATE 1ML INJECTION 151 ATROPINE SULFATE EYE OINTMENT OINTMENT 152 AXILLARY CRUTCHES LARGE 153 AXILLARY CRUTCHES MEDIUM 154 AZELAIC ACID SATCHES 155 AZELASDINE HCL & FLUTICASONE PROPIONATE SPRAY 156 AZELASTINE EYE DROP DROP 157 AZITHROMYCIN 100MG SYRUP 158 AZITHROMYCIN 200MG SYRUP 159 AZITHROMYCIN 250MG TABLET 160 AZITHROMYCIN 500MG INJECTION 161 BACILLUSCALMETTE‐GUERINBCG VACCINE INJECTION 162 BACITRACIN 5000IU,NEOMYCIN 3400IU,POLYMYXINB 400IU‐ 10GM POWDER 163 BACLOFEN 30MG TABLET 164 BACTERIAL FILTER PIECES 165 BALANCED NUTRITION FOR DIABETICS NUTRITION 166 BALANCED NUTRITION HEPATIC CARE NUTRITION 167 BANDAGE 10CM ELASTIC BAND 168 BANDAID BAND‐AID 169 BECLOMETASONE 025% ,NEOMYCIN 1%,CLOTRIMAZOLE 05% CREAM 170 BECLOMETASONE TOPICAL 025%W/V,CLOTRIMAZOLETOPICAL 1%W/V 30ML LOTION BECLOMETASONE TOPICAL 025%W/W,CLOTRIMAZOLE TOPICAL CREAM 171 1%W/V 20GM 172 BECLOMETASONE TOPICAL 025%W/W,CLOTRIMAZOLE TOPICAL 1%W/W,NEOMYCIN CREAM/15 GM 173 BENFOTIAMINE, ALPHA LIPOIC ACID,MECOBALAMIN,VIT B 6 100MG TABLET 174 BENFOTIAMINE 100MG,ALPHA LIPOIC ACID 100MG,MECOBALAMIN 05MG,PYRIDOXINE CAPSULE 175 BENFOTIAMINE 150MG,METHYL COBALAMIN 1500MCG, ALPHA LIPOICACID CAPSULE 176 BENFOTIAMINE COBALAMIN CAPSULE 177 BENZALKONIUM CHIORIDE,CHOLINE SALICYLATE GEL 178 BENZATHINE PENICIILIN 12LA INJECTION 179 BENZOCAINE IP 5GM GEL 180 BENZOYL PENICIILIN 10LA INJECTION 181 BENZOYL PEROXIDE 25% GEL 182 BENZOY LPEROXIDE 5% GEL 183 BENZOYL PEROXIDE 50GM CREAM 184 BENZTHIAZIDE AND TRIAMTERENE TABLET 185 BESACODYL 10MG SUPPOSITARY 186 BESACODYL 5MG TABLET 187 BETAHISTINE 16MG TABLET 188 BETAHISTINE DIHYDRO CHLORIDE 16MG TABLET 189 BETAHISTINE DIHYDRO CHLORIDE 8MG TABLET 190 BETA METHASONE 05%,SALICYLIC ACID 03%) LOTION 191 BETA METHASONE 61MG,CLIOQUINOL (IODOCHLORHYDROXYQUIN)10MG,GENTAMICI OINTMENT 192 BETA METHASONE 4MG INJECTION 193 BETA METHASONE DIPROPIONATE+GENTAMYCIN 16gm CREAM 194 BETA METHASONE TOPICAL 05%W/V 30ML LOTION 195 BETA METHASONE TOPICAL 01%W/W,NEOMYCIN TOPICAL 05%W/W 20GM CREAM 196 BETA METHASONE TOPICAL 01%W/W 20GM CREAM 197 BETAMETHASONE TOPICAL 61MG,CLIOQUINOL (IODOCHLORHYDROXYQUIN) CREAM 10 GM 198 BIOFLAVONOIDS+KOJIC ACID+SODIUM ASCORBYL PHOSPHATE CREAM 199 BIOPSY NEEDLE 16GM PIECES 200 BIPHASIC ISOPHANE INSULIN INJECTION 201 BLADE28 PIECES 202 BLOOD TRANSFUSION SET PIECES 203 BONE WAX W8 102GM) PIECES 204 BOVINE LIPID EXTRACT SURFACTANT 3ML INJECTION 205 BOVINE LIPID EXTRACT SURFACTANT 5ML INJECTION 206 BP MONITOR DIGITAL PIECES 207 BROMFENAC 09% EYE DROP DROP 208 BROMODINE+TIMOLOL EYE DROP DROP 209 BROMODINE TARTRATE EYE DROP DROP 210 BUDESONIDE/FORMOTEROL(‐200MCG/6MCG 1BOTTLE) INHALER 211 BUDESONIDE 100MCG INHALER 212 BUDESONIDE 200MCG INHELAR 213 BUDESONIDE 25ML respules 214 BUPIVACAINE HCL 20ML (0.51) (0.251) INJECTION 215 BUPIVACAINE HCL INDEX TROSE 4ML INJECTION 216 BUTODOL 1ML INJ INJECTION 217 CABERGOLINE 025MG TABLET 218 CABERGOLINE 05MG TABLET 219 CAFFINE CITRATE 20MG 2ML INJECTION 220 CAFFINE CITRATE 20MG 3ML SYRUP 221 CALAMIN 50ml LOTION 222 CALAMINE 100ML LOTION 223 CALAMINE 15% + ZINCOXIDE 5% 60ML LOTION 224 CALAMINE 50ML SOLUTION 225 CALAMINE AND ZINCOXIDE 60ML LOTION 226 CALCIROL 025 MCG+CALCIUM 200MG TABLET 227 CALCITRIOL,CALCIUM CARBONATE AND ZINC CAPSULE 228 CALCITRIOL 025 MCG CAPSULE 229 CALCITRIOL NASAL SOLUTION 200IU SPRAY 230 CALCIUM TABLET 231 CALCIUM,NICOTINAMIDE,PYRIDOXINE,ZINCSULPHATE 100ML SYRUP 232 CALCIUM+ALPHA CALCIDOL TABLET 233 CALCIUM 250MG TABLET 234 CALCIUM 75MG,COPPER 05MG,ELEMENTAL MAGNESIUM 3MG SACHET 235 CALCIUM 75MG,COPPER 05MG,ELEMENTAL MAGNESIUM 3MG TABLET 236 CALCIUM 75MG,COPPER 05MG,ELEMENTAL MAGNESIUM 3MG+MULTIVITAMIN TABLET 237 CALCIUM AND CALCITRIOL TABLET 238 CALCIUM AND VITAMIN D TABLET 239 CALCIUM CARBOMNATE VITAMIN supplements TABLET 240 CALCIUM CARBONATE+CALCIFEROL TABLET 241 CALCIUM CARBONATE+MEGNESIUM SULPHATE TABLET 242 CALCIUM CARBONATE+VITAMIN D3 TABLET 243 085GM 500ML INJECTION 244 CALCIUM CITRATE WITH D3 TABLET 245 CALCIUM DOBESILATE 500MG TABLET 246 CALCIUM GLUCONATE 100ML SYRUP 247 CALCIUM GLUCONATE 10ML INJECTION 248 CALCIUM PANTOTHENATE,FOLIC ACID,NICOTINAMIDE,VITAMIN B1,VITAMIN B12,VITAMIN CAPSULE 249 CALCIUM PHOSPHATE,VITAMIN D3 AND VITAMINB12 200ML SYRUP 250 CALTROPS AND PASANABHEDA HIMALYAN TABLET
Load more

Recommended publications
  • A Systematic Review of Proton Pump Inhibitors for the Treatment of Adult Patients with Symptomatic Gastroesophageal Reflux Disease Or Peptic Ulcer Disease
    Title A systematic review of proton pump inhibitors for the treatment of adult patients with symptomatic gastroesophageal reflux disease or peptic ulcer disease. Review Question(s) Requested Requested by PSD 1. What is the comparative effectiveness of different proton pump inhibitors in patients with symptoms of gastroesophageal reflux disease? 2. What is the comparative effectiveness of different proton pump inhibitors in treating peptic (duodenal and gastric) ulcer? 3. What are the comparative safety and adverse events of different proton pump inhibitors in patients being treated for symptoms of gastroesophageal reflux disease and peptic ulcer? 4. Are there subgroups of patients based on demographics, other medications, or comorbidities (including nasogastric tubes and inability to swallow solid oral medication) for which a particular proton pump inhibitor or preparation is more effective or associated with fewer adverse effects? Drug The following five proton pump inhibitors (PPI) drugs will be reviewed 1. Esomeprazole (Nexium® and its generic equivalent) 2. Lansoprazole (Prevacid® and its generic equivalent) 3. Omeprazole* (Losec® and its generic equivalent) 4. Pantoprazole* sodium and magnesium (Pantoloc®, Panto IV and their generic equivalent and Tecta® 5. Rabeprazole* (Pariet® and its generic equivalent) Note: *Omeprazole, Pantoprazole and Rabeprazole have been identified as reference drugs by PSD. Esomeprazole and Lansoprazole will be compared to these three reference drugs. TABLE OF CONTENTS TABLE OF CONTENTS ..........................................................................................................................2
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Comparative Efficacy of Various Anti-Ulcer Medications After Gastric Endoscopic Submucosal Dissection: a Systematic Review and Network Meta-Analysis
    Surgical Endoscopy (2019) 33:1271–1283 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6409-4 Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis Eun Hye Kim1 · Se Woo Park2 · Eunwoo Nam3 · Jae Gon Lee4 · Chan Hyuk Park4 Received: 4 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection (ESD) has not been fully evaluated. Recently, vonoprazan, a novel potassium-competitive acid blocker, has also been used in ulcer treatment after ESD. Methods We searched for all relevant randomized controlled trials examining the efficacy of anti-ulcer medications after gastric ESD, published through October 2017. Healing of iatrogenic ulcers was investigated at 4–8 weeks after ESD. A network meta-analysis was performed to calculate the network estimates. Results Twenty-one studies with 2005 patients were included. Concerning the comparative efficacy for ulcer healing at 4 weeks after ESD, no network inconsistency was identified (Cochran’s Q-test, df = 10, P = 0.13; I2 = 34%). A combination therapy of proton-pump inhibitor (PPI) and muco-protective agent was superior to PPI alone [risk ratio (RR) (95% confi- dence interval, CI) 1.69 (1.20–2.39)]. The combination therapy of PPI and muco-protective agents tended to be superior to vonoprazan [RR (95% CI) 1.98 (0.99–3.94)]. There was no difference of ulcer healing effect between PPI and vonoprazan [RR (95% CI) PPI vs.
    [Show full text]
  • Bismuth Salts for Gastrointestinal Issues: a Review of the Clinical Effectiveness and Guidelines DATE
    TITLE: Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines DATE: 24 November 2015 CONTEXT AND POLICY ISSUES Oral bismuth formulations have been used effectively for prophylaxis and treatment of both diarrhea and for treatment of Helicobacter pylori (H. pylori) infection.1,2 Bismuth formulations available without a prescription have been commonly used to treat episodic diarrhea for over a century. Bismuth has also been used to treat ulcers prior to the appreciation of its antimicrobial activity against the then unknown causative micro-organism, H. pylori.1 Episodes of diarrhea are especially common in travelers to resource-poor countries. It is estimated that 30% to 70% of international travelers will develop diarrhea during travels or upon return. Typically diarrhea is self-diagnosed and the causal infectious agent remains unknown. While the condition is frequently self-limiting, treatment can reduce the duration, severity, and inconvenience of diarrhea while travelling. Commonly used treatments include antibiotics, antimotility agents, oral rehydration solutions, and bismuth subsalicylate.2 H. pylori infection is a substantial public health concern as it plays a causative role in the pathogenesis of many gastrointestinal conditions such as gastritis, peptic ulcers, and gastric cancer.3 Current treatment regimens designed to eradicate infection utilize more than one antibiotic simultaneously in a standard triple therapy (STT) consisting of a proton-pump inhibitor (PPI), and two antibiotics.
    [Show full text]
  • New and Future Drug Development for Gastroesophageal Reflux Disease
    J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.6 JNM Journal of Neurogastroenterology and Motility Review New and Future Drug Development for Gastroesophageal Reflux Disease Carla Maradey-Romero and Ronnie Fass* The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel- opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)’s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist’s, extended release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies. (J Neurogastroenterol Motil 2014;20:6-16) Key Words Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors Most patients with GERD fall into 1 of 3 categories: non- erosive reflux disease (NERD), erosive esophagitis (EE), and Introduction Barrett’s esophagus (BE). The 2 main phenotypes of GERD, Gastroesophageal reflux disease (GERD) is a common con- NERD and EE, appear to have different pathophysiological and dition that develops when reflux of stomach contents cause trou- clinical characteristics.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Effect of Ilaprazole on the Healing of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Randomized-Controlled, Multicenter Study
    Surgical Endoscopy (2019) 33:1376–1385 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6412-9 Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study Chang Seok Bang1,2 · Woon Geon Shin1,3 · Seung In Seo1 · Min Ho Choi1 · Hyun Joo Jang1 · Se Woo Park1 · Sea Hyub Kae1 · Young Joo Yang1 · Suk Pyo Shin1 · Gwang Ho Baik1 · Hak Yang Kim1 Received: 18 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The optimal treatment regimen or the duration of treatment for an endoscopic submucosal dissection (ESD)- induced gastric ulcer has not been established. The aim of this study was to assess the efficacy of novel proton-pump inhibitor, ilaprazole, for the treatment of ESD-induced gastric ulcer. Methods This was a prospective, open-label, randomized multicenter study. Between June 2015 and March 2018, a total of 176 patients (178 lesions) who underwent ESD for a gastric neoplasm were randomly allocated to receive the oral proton- pump inhibitor ilaprazole 20 mg or rabeprazole 20 mg daily for 8 weeks. The primary outcome was the ulcer healing rate at 4 and 8 weeks. Results A total of 155 (157 lesions) and 154 patients (156 lesions) were included in the modified intention-to-treat (mITT) and per-protocol analyses, respectively. There was no significant difference in the ulcer healing rate (ilaprazole vs. rabepra- zole, 97.4% vs. 97.0 p = 0.78 at 4 weeks, 100% vs. 100%, p = 0.95 at 8 weeks in the mITT analysis) or stage of ulcer (scar stage, 25.6% vs.
    [Show full text]
  • Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Pharmacology & Therapeutics 138 (2013) 103–141 Contents lists available at SciVerse ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: H. Bönisch Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation Ulrich M. Zanger ⁎, Matthias Schwab Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112 D, 70376 Stuttgart, Germany Department of Clinical Pharmacology, The University of Tuebingen Medical Faculty, Tuebingen, Germany article info abstract Keywords: Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 Biotransformation putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, Cytochrome P450 monooxygenase are responsible for the biotransformation of most foreign substances including 70–80% of all drugs in clinical NADPH:cytochrome P450 reductase use. The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and Pharmacogenetics 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically. Expression of each Polymorphism CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, Xenobiotic induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others. Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers.
    [Show full text]
  • Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea
    2017 Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea Aging populations and growing interest in health and welfare continue companies have developed therapies in an array of areas including oncology, antibacterial, gastritis, respiratory to drive up the demand for innovative drugs across the world. Globally, infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction, hepatitis B and hypertension. R&D spending in the pharmaceutical industry was higher than any Development of innovative drugs targeting other industry (pharmaceutical and bio ranked No. 1 with 150 billion Drug development the global market Early years of drug getting on track 2010’s dollars(2015)), indicating that the future industrial structure is shifting Development of development Local manufacturing of 2000’s finished products and new processes from IT to pharmaceutical business. drug substance 1990’s 1980’s 1960/70’s Pharmaceutical Industry in Korea Launch of innovative drugs(total of 27) ’99 ’01 ’02 ’03 ’05 ’06 ’07 ’08 ’10 ’12 ’13 ’14 ’15 2016 In Korean, the value of drugs manufactured in Korea was KRW 16.9 trillion in 2015. The annual average growth rate for the past five years was 4.7 percent. In addition, the size of the pharmaceutical market was KRW 19.2 trillion in 2015. Sunpla EGF Factive Apitoxin Revanex Levovir Pelubi Noltec Pyramax Supect Duvie Riavax Acelex Olita Tab Milican Peudovaccin Zydena Mvix Kanab Zemiglo Zabolante Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion, %) Category
    [Show full text]
  • Pharmacological Management of Gastro-Esophageal Reflux Disease: an Update of the State-Of-The-Art
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art Vincenzo Savarino 1 Abstract: Gastro-esophageal reflux disease (GERD) is a highly prevalent, chronic disorder, Elisa Marabotto1 whose knowledge remains limited and the management of these patients changes continu­ Patrizia Zentilin 1 ously. This review provides a summary of the most recent advancements in the pathogenesis Maria Giulia Demarzo1 of this disease and the new drugs introduced into the market to overcome some of the unmet Nicola de Bortoli2 needs of traditional therapies. Nowadays, the most fruitful diagnostic examinations are 24- hour impedance-pH monitoring, which allows us to separate true NERD from esophageal Edoardo Savarino 3 functional disorders and high-resolution manometry, which helps to exclude the existence of 1Department of Internal Medicine (DIMI), motility disorders sharing the same symptoms of GERD. Proton pump inhibitors (PPIs) University of Genoa, Genoa, Italy; 2Department of Translational Research remain the first-choice therapy in the treatment of GERD, but a consistent proportion of these and New Technologies in Medicine and patients continue to experience symptoms despite their intake. These cases pertain mainly to Surgery, University of Pisa, Pisa, Italy; the subpopulation with non-erosive reflux disease (NERD) and represent very challenging 3Department of Surgery, Oncology and Gastroenterology, University of Padova, clinical situations, because it is mandatory to understand the reasons for PPI failure. The Padova, Italy management of these difficult patients requires necessarily to test them and avoid the use of empiric treatments that are often unsuccessful, costly and potentially dangerous.
    [Show full text]
  • Study Protocol and Also in Accordance with the Following: ! the Ethical Principles That Have Their Origin in the Declaration of Helsinki
    Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo NCT Number: NCT02873702 Protocol Approve Date: 20 February 2017 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information or company confidential information. This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. TITLE PAGE PROTOCOL AMENDMENT A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo Sponsor: Takeda Development Center Asia, Pte. Ltd. 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 Study Number: TAK-390MR_301 IND Number: Not Applicable EudraCT Number: Not Applicable Compound: TAK-390MR Dexlansoprazole Capsules Date: 20 February 2017 Amendment Number: 03 Amendment History: Date Amendment Number Amendment Type Region 05 August 2011 Initial Protocol Not applicable China 16 December 2015 01 Substantial China 09 June 2016 02 Nonsubstantial China 20 February 2017 03 Nonsubstantial China CONFIDENTIAL PROPERTY OF TAKEDA This document is a confidential communication of Takeda.
    [Show full text]